Implementation of a Standardized Medication Therapy Management Plus Approach within Primary Care

References

1. 1.↵
   1. Bartlett G,
   2. Rahimzadeh V,
   3. Longo C,
   4. et al

   . The future of genomic testing in primary care: the changing face of personalized medicine. Per Med 2014;11:477–486.

   OpenUrl
2. 2.↵
   1. de Bakker DH,
   2. Coffie DS,
   3. Heerdink ER,
   4. van Dijk L,
   5. Groenewegen PP

   . Determinants of the range of drugs prescribed in general practice: A cross-sectional analysis. BMC Health Serv Res 2007;7:132.

   OpenUrlCrossRefPubMed
3. 3.↵
   1. Strand LM,
   2. Morley PC,
   3. Cipolle RJ,
   4. Ramsey R,
   5. Lamsam GD

   . Drug-related problems: Their structure and function. DICP 1990;24:1093–1097.

   OpenUrl
4. 4.↵
   1. Gandhi TK,
   2. Weingart SN,
   3. Borus J,
   4. et al

   . Adverse drug events in ambulatory care N Engl J Med 2003;348:1556–1564.

   OpenUrlCrossRefPubMedWeb of Science
5. 5.↵
   1. Goulding MR

   . Inappropriate medication prescribing for elderly ambulatory care patients. Arch Intern Med 2004;164:305–312.

   OpenUrlCrossRefPubMedWeb of Science
6. 6.↵
   1. Bourgeois FT,
   2. Shannon MW,
   3. Valim C,
   4. Mandl KD

   . Adverse drug events in the outpatient setting: An 11-year national analysis. Pharmacoepidemiol Drug Saf 2010;19:901–910.

   OpenUrlCrossRefPubMedWeb of Science
7. 7.↵
   1. Thomsen LA,
   2. Winterstein AG,
   3. Søndergaard B,
   4. Haugbølle LS,
   5. Melander A

   . Systematic review of the incidence and characteristics of preventable adverse drug events in ambulatory care. Ann Pharmacother 2007;41:1411–26.

   OpenUrlCrossRefPubMed
8. 8.↵
   U.S. Department of Health and Human Services, Office of Disease Prevention and Health Promotion. National Action Plan for Adverse Drug Eevent Prevention. Washington, DC; 2014.
9. 9.↵
   Centers for Medicare & Medicaid Services. Medicare Program; Medicare Prescription Drug Benefit. 42 CFR §400, 403, 411, 417, 423. Available from: https://www.federalregister.gov/documents/2005/01/28/05–1321/medicare-program-medicare-prescription-drug-benefit. Published January 28, 2005. Effective March 22, 2005. Accessed September 21, 2016.
10. 10.↵
    Avalere Health. Exploring Pharmacists Role in a Changing Healthcare Environment. Washington, DC; May 2014.
11. 11.↵
    1. Schumock GT,
    2. Butler MG,
    3. Meek PD,
    4. et al

    . Evidence of the economic benefit of clinical pharmacy services: 1996–2000. Pharmacotherapy 2003;23:113–132.

    OpenUrlCrossRefPubMedWeb of Science
12. 12.↵
    1. Lee JK,
    2. Grace KA,
    3. Taylor AJ

    . Effect of a pharmacy care program on medication adherence and persistence, blood pressure, and low-density lipoprotein cholesterol: A randomized controlled trial. JAMA 2006;296:2563–2571.

    OpenUrlCrossRefPubMedWeb of Science
13. 13.↵
    1. Stewart S,
    2. Pearson S,
    3. Horowitz JD

    . Effects of a home-based intervention among patients with congestive heart failure discharged from acute hospital care. Arch Intern Med 1998;158:1067–1072.

    OpenUrlCrossRefPubMedWeb of Science
14. 14.↵
    1. Gattis WA,
    2. Hasselblad V,
    3. Whellan DJ,
    4. O’Connor CM

    . Reduction in heart failure events by the addition of a clinical pharmacist to the heart failure management team: Results of the Pharmacist in Heart Failure Assessment Recommendation and Monitoring (PHARM) Study. Arch Intern Med 1999;159:1939–1945.

    OpenUrlCrossRefPubMedWeb of Science
15. 15.↵
    1. Rainville EC

    . Impact of pharmacist interventions on hospital readmissions for heart failure. Am J Health Syst Pharm 1999;56:1339–1342.

    OpenUrlPubMedWeb of Science
16. 16.↵
    1. O’Dell KM,
    2. Kucukarslan SN

    . Impact of the clinical pharmacist on readmission in patients with acute coronary syndrome. Ann Pharmacother 2005;39:1423–1427.

    OpenUrlCrossRefPubMed
17. 17.↵
    1. Chapman NR,
    2. Fotis MA,
    3. Yarnold PR,
    4. Gheorghiade M

    . Pharmacist interventions to improve the management of coronary artery disease. Am J Health Syst Pharm 2004;61:2672–2678.

    OpenUrlFREE Full Text
18. 18.↵
    1. DiMatteo MR,
    2. Giordani PJ,
    3. Lepper HS,
    4. Croghan TW

    . Patient adherence and medical treatment outcomes: A meta-analysis. Med Care 2002;40:794–811.

    OpenUrlCrossRefPubMedWeb of Science
19. 19.↵
    1. Pellegrino AN,
    2. Martin MT,
    3. Tilton JJ,
    4. Touchette DR

    . Medication therapy management services: Definitions and outcomes. Drugs 2009;69:393–406.

    OpenUrlCrossRefPubMedWeb of Science
20. 20.↵
    1. Ramalho de Oliveira D,
    2. Brummel AR,
    3. Miller DB

    . Medication therapy management: 10 years of experience in a large integrated health care system. J Manag Care Pharm 2010;16:185–195.

    OpenUrlPubMed
21. 21.↵
    1. Perlroth D,
    2. Marrufo G,
    3. Montesinos A,
    4. et al.

    , eds. Medication therapy management in chronically ill populations: Final report. Baltimore, MD: Centers for Medicare & Medicaid Services; 2013 Aug. Contract No. HHSM-500-2011-00012I/TOT0001.
22. 22.↵
    U.S. Department of Health and Human Services, Centers for Medicare & Medicaid Services. Announcement of part D enhanced medication therapy management model test. Baltimore, MD. September 28, 2015.
23. 23.↵
    1. Hirsch JD,
    2. Steers N,
    3. Adler DS,
    4. et al

    . Primary care-based, pharmacist-physician collaborative medication-therapy management of hypertension: a randomized, pragmatic trial. Clin Ther 2014;36:1244–1254.

    OpenUrlCrossRefPubMed
24. 24.↵
    1. Koenigsfeld CF,
    2. Horning KK,
    3. Logemann CD,
    4. Schmidt GA

    . Medication therapy management in the primary care setting: A pharmacist-based pay-for-performance project. J Pharm Pract 2012;25:89–95.

    OpenUrlCrossRefPubMed
25. 25.↵
    1. Thumar R,
    2. Zaiken K

    . Impact of live medication therapy management on cholesterol values in patients with cardiovascular disease. J Am Pharm Assoc (2003) 2014;54:526–529.

    OpenUrl
26. 26.↵
    1. Isetts BJ,
    2. Buffington DE,
    3. Carter BL,
    4. Smith M,
    5. Polgreen LA,
    6. James PA

    . Evaluation of pharmacists’ work in a physician-pharmacist collaborative model for the management of hypertension. Pharmacotherapy 2016;36:374–384.

    OpenUrlCrossRefPubMed
27. 27.↵
    1. Pherson EC,
    2. Shermock KM,
    3. Efird LE,
    4. et al

    . Development and implementation of a postdischarge home-based medication management service. Am J Health Syst Pharm 2014;71:1576–1583.

    OpenUrlAbstract/FREE Full Text
28. 28.↵
    1. Nassaralla CL,
    2. Naessens JM,
    3. Chaudhry R,
    4. Hansen MA,
    5. Scheitel SM

    . Implementation of a medication reconciliation process in an ambulatory internal medicine clinic. Qual Saf Health Care 2007;16:90–94.

    OpenUrlAbstract/FREE Full Text
29. 29.↵
    1. Moaddeb J,
    2. Mills R,
    3. Haga SB

    . Community pharmacists’ experience with pharmacogenetic testing. J Am Pharm Assoc (2003) 2015;55:587–594.

    OpenUrl
30. 30.↵
    1. Haga SB,
    2. LaPointe NM,
    3. Cho A,
    4. et al

    . Pilot study of pharmacist-assisted delivery of pharmacogenetic testing in a primary care setting. Pharmacogenomics 2014;15:1677–1686.

    OpenUrlCrossRefPubMed
31. 31.↵
    1. Ferreri SP,
    2. Greco AJ,
    3. Michaels NM,
    4. et al

    . Implementation of a pharmacogenomics service in a community pharmacy. J Am Pharm Assoc (2003) 2014;54:172–180.

    OpenUrlCrossRef
32. 32.↵
    1. Swen JJ,
    2. van der Straaten T,
    3. Wessels JA,
    4. et al

    . Feasibility of pharmacy-initiated pharmacogenetic screening for CYP2D6 and CYP2C19. Eur J Clin Pharmacol 2012;68:363–370.

    OpenUrlCrossRefPubMed
33. 33.↵
    1. Morisky DE,
    2. Green LW,
    3. Levine DM

    . Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care 1986;24:67–74.

    OpenUrlCrossRefPubMedWeb of Science
34. 34.↵
    1. Bain KT,
    2. Knowlton CH,
    3. Turgeon J

    . Medication risk mitigation: Coordinating and collaborating with health care systems, universities, and researchers to facilitate the design and execution of practice-based research. Clin Geriatr Med 2017;33:257–281.

    OpenUrl
35. 35.↵
    1. Marathe PH,
    2. Gao HX,
    3. Close KL

    . American Diabetes Association standards of Medical Care in Diabetes 2017. J Diabetes 2017;9:320–324.

    OpenUrlPubMed
36. 36.↵
    1. Yancy CW,
    2. Jessup M,
    3. Bozkurt B,
    4. et al

    . 2013 ACCF/AHA guideline for the management of heart failure: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013;62(16):e147–e239.

    OpenUrlFREE Full Text
37. 37.↵
    1. Yancy CW,
    2. Jessup M,
    3. Bozkurt B,
    4. et al

    . 2016 ACC/AHA/hfsa focused update on new pharmacological therapy for heart failure: An update of the 2013 ACCF/AHA Guideline for the management of heart failure: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Am Coll Cardiol 2016;68:1476–1488.

    OpenUrlFREE Full Text
38. 38.↵
    1. Relling MV,
    2. Klein TE

    . CPIC: Clinical pharmacogenetics implementation consortium of the Pharmacogenomics Research Network. Clin Pharmacol Ther 2011;89:464–467.

    OpenUrlCrossRefPubMedWeb of Science
39. 39.↵
    1. Tubbesing G,
    2. Chen FM

    . Insights from exemplar practices on achieving organizational structures in primary care. J Am Board Fam Med 2015;28:190–194.

    OpenUrlAbstract/FREE Full Text
40. 40.↵
    1. Reiss SM

    . Integrating pharmacogenomics into pharmacy practice via medication therapy management. J Am Pharm Assoc (2003) 2011;51:e64–e74.

    OpenUrl
41. 41.↵
    1. Haga SB,
    2. Moaddeb J,
    3. Mills R,
    4. Patel M,
    5. Kraus W,
    6. Allen LaPointe NM

    . Incorporation of pharmacogenetic testing into medication therapy management. Pharmacogenomics 2015;16:1931–1941.

    OpenUrl
42. 42.↵
    1. Gervasini G,
    2. Benítez J,
    3. Carrillo JA

    . Pharmacogenetic testing and therapeutic drug monitoring are complementary tools for optimal individualization of drug therapy. Eur J Clin Pharmacol 2010;66:755–774.

    OpenUrlPubMed
43. 43.↵
    1. Haga SB,
    2. Allen LaPointe NM,
    3. Moaddeb J,
    4. Mills R,
    5. Patel M,
    6. Kraus WE

    . Pilot study: Incorporation of pharmacogenetic testing in medication therapy management services. Pharmacogenomics 2014;15:1729–1737.

    OpenUrl
44. 44.↵
    1. Valdes R,
    2. Payne DA,
    3. Linder MW

    1. Shaw L,
    2. Burckhart G

    . Therapeutic drug monitoring and pharmacogenetics interface considerations. In: Valdes R, Payne DA, Linder MW, eds. Laboratory medicine practice guidelines: Guidelines and recommendations for laboratory analysis and application of pharmacogenetics to clinical practice. Washington, DC: National Academy of Clincal Biochemistry; 2010; 29–33.
45. 45.↵
    ASHP statement on the pharmacist’s role in clinical pharmacogenomics. Am J Health Syst Pharm 2015;72:579–581.

    OpenUrlFREE Full Text
46. 46.↵
    1. Caudle KE,
    2. Klein TE,
    3. Hoffman JM,
    4. et al

    . Incorporation of pharmacogenomics into routine clinical practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline development process. Curr Drug Metab 2014;15:209–217.

    OpenUrlCrossRefPubMed
47. 47.↵
    1. Crews KR,
    2. Cross SJ,
    3. McCormick JN,
    4. et al

    . Development and implementation of a pharmacist-managed clinical pharmacogenetics service. Am J Health Syst Pharm 2011;68:143–150.

    OpenUrlAbstract/FREE Full Text
48. 48.↵
    1. Haga SB

    . Delivering pharmacogenetic testing to the masses: An achievable goal? Pharmacogenomics 2014;15:1–4.

    OpenUrl
49. 49.↵
    1. O’Connor SK,
    2. Ferreri SP,
    3. Michaels NM,
    4. et al

    . Exploratory planning and implementation of a pilot pharmacogenetic program in a community pharmacy. Pharmacogenomics 2012;13:955–962.

    OpenUrlCrossRefPubMed
50. 50.↵
    US Food and Drug Administration. Table of Pharmacogenomic Biomarkers in Drug Labeling. Available from: https://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm083378.htm. Accessed June 1, 2017.
51. 51.↵
    1. Verbeurgt P,
    2. Mamiya T,
    3. Oesterheld J

    . How common are drug and gene interactions? Prevalence in a sample of 1143 patients with CYP2C9, CYP2C19 and CYP2D6 genotyping. Pharmacogenomics 2014;15:655–665.

    OpenUrlCrossRefPubMed
52. 52.↵
    1. Hocum BT,
    2. White JR Jr.,
    3. Heck JW,
    4. et al

    . Cytochrome P-450 gene and drug interaction analysis in patients referred for pharmacogenetic testing. Am J Health Syst Pharm 2016;73:61–67.

    OpenUrlAbstract/FREE Full Text
53. 53.↵
    1. Cardelli M,
    2. Marchegiani F,
    3. Corsonello A,
    4. Lattanzio F,
    5. Provinciali M

    . A review of pharmacogenetics of adverse drug reactions in elderly people. Drug Saf 2012;35(Suppl 1):3–20.

    OpenUrl
54. 54.↵
    1. Haga SB,
    2. Burke W,
    3. Ginsburg GS,
    4. Mills R,
    5. Agans R

    . Primary care physicians’ knowledge of and experience with pharmacogenetic testing. Clin Genet 2012;82:388–394.

    OpenUrlCrossRefPubMed